OBJECTIVE: This study examined the feasibility and acceptability of an Individual Internet Intervention (III) embedded and integrated into an Internet Support Group (ISG) with the ultimate goal of enhancing adherence and learning, compared with an individual internet invention alone. METHOD:Thirty-one posttreatment cancer survivors were randomized in groups of seven to nine to either the 8-week III + ISG intervention or the 8-week III condition. Seventeen participants met the Hospital Anxiety and Depression Scale (HADS) criteria for depressive symptoms (HADS ≥ 8). RESULTS: Among all participants, the mean number of logins over 8 weeks was 20.8 ± 17.7 logins for the III + ISG compared with 12.5 ± 12.5 in III-only (p = 0.15). Two participants in the III + ISG dropped out, compared with five in III (p = 0.39). Among the 17 participants withdepressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d = 1.27 and 0.89, respectively). Improvement over time and time x treatment effects only reached trend significance levels (ps = 0.07 & 0.12) as this pilot was not powered to detect these differences. CONCLUSION: Both the III + ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression. Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study, these results indicate that pursuing the III + ISG model, as well as standard IIIs, may be fruitful areas of future research.
RCT Entities:
OBJECTIVE: This study examined the feasibility and acceptability of an Individual Internet Intervention (III) embedded and integrated into an Internet Support Group (ISG) with the ultimate goal of enhancing adherence and learning, compared with an individual internet invention alone. METHOD: Thirty-one posttreatment cancer survivors were randomized in groups of seven to nine to either the 8-week III + ISG intervention or the 8-week III condition. Seventeen participants met the Hospital Anxiety and Depression Scale (HADS) criteria for depressive symptoms (HADS ≥ 8). RESULTS: Among all participants, the mean number of logins over 8 weeks was 20.8 ± 17.7 logins for the III + ISG compared with 12.5 ± 12.5 in III-only (p = 0.15). Two participants in the III + ISG dropped out, compared with five in III (p = 0.39). Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d = 1.27 and 0.89, respectively). Improvement over time and time x treatment effects only reached trend significance levels (ps = 0.07 & 0.12) as this pilot was not powered to detect these differences. CONCLUSION: Both the III + ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression. Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study, these results indicate that pursuing the III + ISG model, as well as standard IIIs, may be fruitful areas of future research.
Authors: Andrew J Winzelberg; Catherine Classen; Georg W Alpers; Heidi Roberts; Cheryl Koopman; Robert E Adams; Heidemarie Ernst; Parvati Dev; C Barr Taylor Journal: Cancer Date: 2003-03-01 Impact factor: 6.860
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Mark S Salzer; Steven C Palmer; Katy Kaplan; Eugene Brusilovskiy; Thomas Ten Have; Maggie Hampshire; James Metz; James C Coyne Journal: Psychooncology Date: 2010-04 Impact factor: 3.894
Authors: David C Mohr; Jennifer Duffecy; Ling Jin; Evette J Ludman; Adam Lewis; Mark Begale; Martin McCarthy Journal: J Med Internet Res Date: 2010-12-19 Impact factor: 5.428
Authors: Lynne I Wagner; Jenna Duffecy; Mark Begale; David Victorson; Shannon L Golden; Mary Lou Smith; Frank J Penedo; David C Mohr; David Cella Journal: Psychooncology Date: 2020-01-08 Impact factor: 3.894
Authors: Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Joan M Romano; Marie-Laure Crouch; Allison S Fiscalini; Mark T Hegel; Mary E D Flowers; Paul J Martin; Wendy M Leisenring Journal: J Cancer Surviv Date: 2018-05-05 Impact factor: 4.442
Authors: N Fridriksdottir; S Gunnarsdottir; S Zoëga; B Ingadottir; E J G Hafsteinsdottir Journal: Support Care Cancer Date: 2017-09-18 Impact factor: 3.603
Authors: Karen L Syrjala; Marie-Laure Crouch; Wendy M Leisenring; Mary E D Flowers; Samantha B Artherholt; Allison Stover Fiscalini; Eleni Romano; Joan M Romano; Paul J Martin; Jean C Yi Journal: Biol Blood Marrow Transplant Date: 2018-05-09 Impact factor: 5.742